中老年人骨质疏松症药物使用——加拿大《骨质疏松症管理和骨折预防临床实践指南(2023版)》解读  

Drug use among the elderly with osteoporosis-interpretation on clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update

作　　者：周轶 史琛[1] Zhou Yi;Shi Chen(Department of Pharmacy,Tongji Medical college,Huazhong University of Science and Technology,wuhan 430000,China)

机构地区：[1]华中科技大学同济医学院附属协和医院药学部,武汉430000

出　　处：《中华老年医学杂志》2025年第2期141-148,共8页Chinese Journal of Geriatrics

摘　　要：随着我国人口老龄化程度加深,骨质疏松症及由此引发的骨折愈发值得关注。2023年10月加拿大骨质疏松症指南更新小组在2010版基础上更新、制定并发布了加拿大《骨质疏松症管理和骨折预防临床实践指南(2023版)》,旨在帮助加拿大初级卫生保健专业人员筛查居住在社区的中老年人是否存在骨质疏松症和骨折的危险因素,并提供干预措施以优化骨骼健康和骨折预防。本文将结合指南的要点、循证医学证据以及最新临床实践,对新版指南中关于中老年人骨质疏松症的运动锻炼、营养补充及药物治疗相关临床问题进行解读。With the aging population in China,the prevalence of osteoporosis and associated fractures is becoming increasingly concerning.In October 2023,the Canadian Osteoporosis Guideline Update Group published the"Clinical Practice Guideline for Management of Osteoporosis and Fracture Prevention in Canada:2023 Update",which builds upon the 2010 edition.The primary objective of this guideline is to assist primary healthcare professionals in Canada in screening for osteoporosis and fracture risk factors among middle-aged and elderly individuals residing in the community,as well as to provide interventions aimed at optimizing skeletal health and preventing fractures.This article will focus on interpreting the clinical issues related to exercise,nutritional supplementation,and pharmacological treatment for middle-aged and elderly individuals with osteoporosis as outlined in the new guidelines,integrating key points from the guidelines,evidence-based medical literature,and the latest clinical practices.

关 键 词：骨质疏松 骨折 药物疗法 

分 类 号：R580[医药卫生—内分泌]